MedTrace Logo

Antihistamines, Amantadine and Evolution of COVID-19

NCT05504057 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 140660

Last updated 2026-04-03

No results posted yet for this study

Summary

The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.

Conditions

Interventions

DRUG

Antihistamine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines

DRUG

Amantadine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine

Sponsors & Collaborators

  • Institut Català de la Salut

    collaborator OTHER

  • Consorci Sanitari de Terrassa

    lead OTHER

Principal Investigators

  • Anna Puigdellívol, PhD · Terrassa Health Consortium

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2025-01-19
Completion
2028-02-24
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05504057 on ClinicalTrials.gov